VANCOUVER, British Columbia,
March 12, 2013 /PRNewswire/
-- Abattis Bioceuticals Corp (OTC PINK: ATTBF) (CNSX: FLU)
today announced that it has provided $10,000 sponsorship for the cannabis
(cannabis sp.) monograph and therapeutic compendium
currently under development by the American Herbal Pharmacopoeia
(AHP).
The monograph, scheduled for release in Spring 2013, will
provide industry with a variety of scientifically valid analytical
methods suitable for use in the identification, purity, and quality
assessment of cannabis and its crude products.
Health Canada has recently
proposed changes to the Canada's
Marijuana Medical Access Program that aims to treat marijuana as it
does any prescribed drug, allowing for legal commercial production
for those who meet specific requirements.
"This generous sponsorship from Abattis Bioceuticals will
facilitate the completion of this important and timely monograph,"
said Roy Upton, executive director
of AHP. "There is a critical need for quality controls to be
put in place in the cannabis industry to ensure valid and
appropriate testing methodologies, and the AHP monograph will help
to create greater transparency and establish standard methods of
analysis."
"We are extremely proud to support the development of this
monograph by AHP," said Mr. Michael
Withrow, Abattis' chief executive officer. He went on to
say, "There is a strong need for the development of transparent
standards for cannabis and its products and an incredible need for
objective and critical review of the therapeutic and safety data on
cannabis, especially now as the laws are being changed to allow for
multiple uses of this misunderstood botanical. The world needs
standards for Cannabis and the many phytochemicals that come from
it so lawmakers can properly categorize them and so formulators can
legally apply the compounds in appropriate products that help those
who are suffering from various chronic diseases."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp., based in Langley, B.C., is a specialty biotechnology
company with capabilities through its wholly owned subsidiaries of
growing, producing, licensing and marketing proprietary ingredients
and products containing standardized phytochemicals for sale in the
pharmaceuticals, nutraceuticals, cosmetics, and animal nutrition
markets. The company also has a deep pipeline of proprietary
products ready for sale in high-growth areas of functional foods
and dietary supplements business. For more information, visit the
company's website at www.abattis.com.
About the American Herbal Pharmacopoeia
The American Herbal Pharmacopoeia is a non-profit 501C(3),
California-based research
organization with a mission to promote the responsible use of
herbal products and herbal medicines through the production of
critically reviewed monographs that outline the quality control
criteria needed for ensuring the identity, purity, and quality of
botanical raw materials. Founded in 1995, AHP has monographs on 35
different botanicals. For more information, visit AHP's website,
http://www.herbal-ahp.org/index.html.
ON BEHALF OF THE BOARD
"Michael Withrow"
Michael Withrow, President &
CEO
Mr. Mike Withrow
778-896-6536
Neither the CNSX Exchange nor its
regulations services accepts responsibility for the adequacy
or accuracy of this release.
Forward-looking
information
All statements included in this
press release that address activities, events or developments that
the Company expects, believes or anticipates will or may occur in
the future are forward-looking statements. These
forward-looking statements involve numerous assumptions made by the
Company based on its experience, perception of historical trends,
current conditions, expected future developments and other factors
it believes are appropriate in the circumstances. In
addition, these statements involve substantial known and unknown
risks and uncertainties that contribute to the possibility that the
predictions, forecasts, projections and other forward-looking
statements will prove inaccurate, certain of which are beyond the
Company's control. There can be no assurance that any
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should
not place undue reliance on forward-looking statements.
Except as required by law, the Company does not intend to revise or
update these forward-looking statements after the date hereof or to
revise them to reflect the occurrence of future unanticipated
events.
SOURCE Abattis Bioceuticals Corp.
